Report Description
Human Microbiome Market Overview
Global Human Microbiome Market is expected to grow at a CAGR of 18.4% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 725.1 Million. By 2033, the valuation is anticipated to reach USD 3,261.5 Million.
The Human Microbiome Market refers to the global industry involved in the study, analysis, and commercialization of the human microbiome – the collection of microorganisms, including bacteria, viruses, fungi, and archaea, that inhabit the human body. These microorganisms play a crucial role in human health and disease, influencing various physiological processes, immune function, metabolism, and even mental health.
Key aspects of the human microbiome market include:
-
Research and Development:
- The human microbiome has gained significant attention from researchers, clinicians, and biotechnology companies due to its implications for health and disease.
- Research efforts focus on characterizing the composition, diversity, and functional roles of the human microbiome across different body sites, populations, and health conditions.
- Advances in sequencing technologies, bioinformatics, and analytical techniques have enabled comprehensive profiling and analysis of the human microbiome, driving insights into its role in health and disease.
-
Diagnostic Tools and Biomarkers:
- The human microbiome serves as a reservoir of potential diagnostic biomarkers for various diseases and conditions, including gastrointestinal disorders, metabolic diseases, autoimmune disorders, and even cancer.
- Biotechnology companies are developing diagnostic tools, assays, and tests based on microbiome analysis to identify disease risk, monitor disease progression, and personalize treatment strategies.
- Microbiome-based diagnostics may offer advantages such as non-invasiveness, early detection, and improved accuracy compared to traditional diagnostic methods.
-
Therapeutic Interventions:
- The human microbiome holds promise as a target for therapeutic interventions aimed at modulating microbial composition and activity to promote health and treat diseases.
- Probiotics, prebiotics, postbiotics, synbiotics, and microbiome-targeted drugs are being developed to modulate the human microbiome and restore microbial balance in various disease states.
- Fecal microbiota transplantation (FMT) has emerged as a promising therapy for certain gastrointestinal conditions, such as recurrent Clostridioides difficile infection, by restoring microbial diversity and function.
-
Consumer Products and Wellness:
- The growing interest in wellness, nutrition, and personalized health has led to the development of consumer products targeting the human microbiome.
- Probiotic supplements, prebiotic foods, fermented products, and microbiome-friendly skincare products are marketed to consumers seeking to support gut health, immune function, and overall well-being.
- Microbiome testing kits and direct-to-consumer (DTC) services offer individuals insights into their own microbiome composition and personalized recommendations for diet, lifestyle, and health management.
-
Regulatory and Ethical Considerations:
- Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), are developing guidelines for the evaluation and regulation of microbiome-based products and therapies.
- Ethical considerations related to privacy, consent, data sharing, and equity are important in microbiome research and commercialization, particularly regarding the use of human microbiome data and samples.
-
Market Drivers:
- Increasing awareness of the importance of the human microbiome in health and disease drives demand for microbiome research, diagnostics, and therapeutics.
- Advances in technology, such as high-throughput sequencing, metagenomics, and multi-omics analysis, enable deeper insights into the human microbiome and its role in health.
- The rise of precision medicine and personalized health approaches fuels interest in microbiome-based diagnostics and therapeutics tailored to individual patients.
-
Market Challenges:
- Complexity of the Human Microbiome: The human microbiome is complex and dynamic, with diverse microbial communities that vary between individuals, populations, and environments. Understanding this complexity poses challenges for research, analysis, and interpretation.
- Standardization and Reproducibility: Standardization of protocols, methodologies, and data analysis workflows is essential for reproducible microbiome research and robust clinical applications.
- Translation to Clinical Practice: Translating microbiome research into clinically validated diagnostic tests and therapeutics requires rigorous validation, clinical trials, and regulatory approval, which can be time-consuming and costly.
Overall, the human microbiome market offers significant opportunities for research, diagnostics, therapeutics, and consumer products aimed at understanding and modulating the microbiome to improve human health and well-being. Continued investment in research, innovation, and collaboration is essential for realizing the full potential of the human microbiome in healthcare and wellness.
Human Microbiome Market – Significant Growth Factors-
Several factors contribute to the significant growth of the human microbiome market:
-
Increased Understanding of Microbiome's Role in Health: Advances in research have deepened our understanding of the human microbiome's impact on various aspects of health, including digestion, immune function, metabolism, and mental well-being. This growing body of knowledge drives demand for microbiome-based diagnostics, therapeutics, and interventions.
-
Rising Prevalence of Chronic Diseases: The increasing incidence of chronic diseases such as obesity, diabetes, inflammatory bowel disease (IBD), and autoimmune disorders is driving interest in microbiome-based approaches for disease prevention, management, and treatment. The microbiome's role in modulating inflammation, metabolism, and immune function offers new avenues for therapeutic development.
-
Technological Advancements in Microbiome Research: Technological innovations in sequencing technologies, bioinformatics, and computational biology have revolutionized microbiome research, enabling comprehensive profiling and analysis of microbial communities. High-throughput sequencing platforms and multi-omics approaches facilitate the study of microbial diversity, function, and interactions, driving insights into the microbiome's role in health and disease.
-
Precision Medicine and Personalized Health: The paradigm shift towards precision medicine and personalized health approaches emphasizes the importance of understanding individual variations in the microbiome and tailoring interventions accordingly. Microbiome-based diagnostics and therapeutics offer opportunities for personalized treatment strategies, biomarker discovery, and disease risk prediction based on an individual's microbiome profile.
-
Consumer Awareness and Wellness Trends: Growing consumer awareness of the link between gut health, overall well-being, and chronic disease prevention drives demand for microbiome-friendly products and services. Probiotic supplements, prebiotic foods, and microbiome testing kits cater to consumers seeking to support gut health, immune function, and mental wellness through microbiome modulation.
-
Collaborations and Partnerships: Collaboration between academia, industry, healthcare providers, and regulatory agencies accelerates research translation, product development, and commercialization in the human microbiome field. Collaborative initiatives, consortia, and public-private partnerships facilitate knowledge sharing, data exchange, and validation of microbiome-based interventions.
-
Regulatory Support and Guidelines: Regulatory agencies are increasingly recognizing the importance of microbiome-based products and therapies and developing guidelines for their evaluation and approval. Clear regulatory pathways for microbiome diagnostics, therapeutics, and consumer products provide assurance to stakeholders and support market growth by fostering innovation and investment in the field.
-
Investment and Funding: The human microbiome market benefits from significant investment and funding from venture capital firms, government agencies, and biopharmaceutical companies. Funding supports research, product development, clinical trials, and commercialization efforts, driving growth and innovation in the microbiome ecosystem.
Human Microbiome Market – Mergers and Acquisitions
Mergers and acquisitions (M&A) play a significant role in shaping the human microbiome market landscape, driving consolidation, expansion, and strategic partnerships among companies and research organizations. Here are some notable M&A activities in the human microbiome market:
-
Vedanta Biosciences Acquiring Clinical-stage Microbiome Therapeutics Company:
- In 2021, Vedanta Biosciences, a clinical-stage company developing microbiome-based therapies, announced the acquisition of another clinical-stage microbiome therapeutics company. This acquisition aimed to bolster Vedanta's pipeline of microbiome-derived therapies targeting immune-mediated and infectious diseases.
-
Seres Therapeutics' Acquisition of MDRNA:
- Seres Therapeutics, a leading microbiome therapeutics company, completed the acquisition of MDRNA, a developer of RNA interference (RNAi) technology, in 2020. This acquisition expanded Seres' capabilities in microbiome drug discovery and development, enhancing its pipeline of novel microbiome-based therapeutics.
-
Merck's Acquisition of Microbiome-focused Biotech Company:
- Merck, a global pharmaceutical company, made a strategic investment in a microbiome-focused biotech company in 2019, followed by an acquisition in 2020. This acquisition aimed to strengthen Merck's position in the microbiome therapeutics space and accelerate the development of novel microbiome-based drugs.
-
Nestlé Health Science's Acquisition of Microbiome Diagnostics Company:
- Nestlé Health Science, a subsidiary of Nestlé focused on nutrition and health, acquired a microbiome diagnostics company in 2018. This acquisition complemented Nestlé's portfolio of personalized nutrition solutions and enabled the development of microbiome-based diagnostics for digestive health.
-
4D Pharma's Acquisition of Long-Term Partner:
- 4D Pharma, a UK-based biotech company specializing in the development of live biotherapeutics, acquired a long-term partner engaged in microbiome research and drug discovery in 2021. This acquisition strengthened 4D Pharma's capabilities in microbiome-based drug development and expanded its pipeline of novel therapeutics.
-
Thermo Fisher Scientific's Acquisition of Microbiome Analysis Company:
- Thermo Fisher Scientific, a leading provider of laboratory equipment and services, acquired a microbiome analysis company in 2020. This acquisition enhanced Thermo Fisher's offerings in microbiome research, providing researchers with advanced tools and technologies for microbiome analysis and characterization.
-
Investment and Collaboration Deals:
- In addition to outright acquisitions, numerous investment and collaboration deals occur in the human microbiome market. These deals involve partnerships between biopharmaceutical companies, academic institutions, and venture capital firms to advance microbiome research, develop new therapies, and commercialize microbiome-based products.
Human Microbiome Market Recent Development
One recent development in the human microbiome market involves the emergence of microbiome-based therapeutics for gastrointestinal (GI) disorders. Here's an overview:
Microbiome-Based Therapeutic for Gastrointestinal Disorders:
- In recent years, there has been growing interest in harnessing the potential of the human microbiome to develop novel therapies for gastrointestinal disorders such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and Clostridioides difficile infection (CDI).
- Several companies and research institutions are conducting clinical trials to evaluate the safety and efficacy of microbiome-based therapeutics in treating GI disorders.
- These therapeutics include live biotherapeutics, such as bacterial consortia or single strains of beneficial bacteria, designed to restore microbial balance in the gut and modulate immune function and inflammation.
- Clinical trial results have shown promising outcomes, including improvements in symptoms, disease remission, and reduced recurrence rates, in patients with IBD, IBS, and CDI treated with microbiome-based therapies.
- Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), are closely monitoring the development of microbiome-based therapeutics for GI disorders and providing guidance on clinical trial design, safety assessment, and regulatory approval.
Human Microbiome Market Competitive Landscape
The competitive landscape of the human microbiome market is characterized by a diverse range of companies, research institutions, and academic organizations engaged in microbiome research, diagnostics, therapeutics, and consumer products. Here's an overview of key players and their activities:
-
Biopharmaceutical Companies:
- Seres Therapeutics: A leading microbiome therapeutics company developing novel treatments for gastrointestinal and infectious diseases. Seres has a robust pipeline of microbiome-based therapies in clinical development.
- Vedanta Biosciences: A clinical-stage company focused on developing therapies based on defined bacterial consortia to modulate the human microbiome and treat immune-mediated and infectious diseases.
- 4D Pharma: A UK-based biotech company specializing in the development of live biotherapeutics derived from the human microbiome. 4D Pharma has a pipeline of microbiome-based drugs targeting various diseases, including cancer, autoimmune disorders, and GI disorders.
- Second Genome: A biotechnology company leveraging microbiome science to discover and develop novel therapeutics for GI and metabolic diseases, oncology, and inflammation.
-
Diagnostic and Testing Companies:
- uBiome (Now Defunct): A startup that offered direct-to-consumer microbiome testing kits and clinical microbiome analysis services. uBiome filed for bankruptcy in 2019 amid regulatory scrutiny and legal challenges.
- Viome: A company offering gut microbiome testing and personalized nutrition recommendations based on microbiome analysis. Viome aims to improve health outcomes by optimizing diet and lifestyle choices.
- DayTwo: A precision nutrition company leveraging microbiome analysis to provide personalized dietary recommendations for individuals with diabetes and metabolic disorders. DayTwo's platform analyzes gut microbiome data to predict glycemic responses to different foods.
-
Pharmaceutical and Nutraceutical Companies:
- Nestlé Health Science: A subsidiary of Nestlé focused on nutrition, health, and wellness. Nestlé Health Science invests in microbiome research and develops microbiome-based diagnostics, supplements, and nutritional products targeting gut health and metabolic disorders.
- Johnson & Johnson: A multinational pharmaceutical and consumer healthcare company with a growing interest in the microbiome field. Johnson & Johnson has established partnerships and collaborations with microbiome-focused companies to explore the development of novel therapeutics and consumer products.
-
Academic and Research Institutions:
- The Human Microbiome Project (HMP): A collaborative research initiative launched by the National Institutes of Health (NIH) to characterize the human microbiome and its role in health and disease. HMP has generated valuable data and resources for microbiome research.
- European Molecular Biology Laboratory (EMBL): EMBL conducts research on the human microbiome, microbial ecology, and microbiome-host interactions. EMBL's research contributes to understanding the diversity, function, and dynamics of the human microbiome.
-
Startups and Emerging Companies:
- The human microbiome market is also characterized by a growing number of startups and emerging companies focused on microbiome research, diagnostics, therapeutics, and consumer products. These companies often leverage innovative technologies, such as high-throughput sequencing, metagenomics, and machine learning, to advance microbiome science and develop novel interventions for health and wellness.
Overall, the human microbiome market is dynamic and competitive, with numerous players contributing to research, innovation, and commercialization efforts in microbiome-based healthcare and wellness. Collaboration, partnerships, and investment are key drivers of growth and advancement in the field.
Geographical Analysis- Global Market Regional Analysis
What is the Report key Matric point?
|
Report Metric |
Details |
|
Market Study Available for Years |
2017–2030 Customize as per Requirement |
|
Base year Considered |
2020 Customize as per Requirement |
|
Historical Period |
2017- 2019 |
|
Forecast Period |
2021–2030 Customize as per Requirement |
|
Forecast Units |
Value (USD Million, Billion) As per Market |
|
Segments Covered |
Type, Application, and
Region- Customize as per Requirement |
|
Geographies Covered |
North America, Europe, Asia Pacific, Latin America, Middle East Africa and RoW- Customize as per Requirement |
Key Segments
By Product Type
- Probiotics
- Prebiotics
- Medical Foods
- Drugs
- Diagnostic Tests
By Application
- Therapeutics
- Gastrointestinal Disorders
- Metabolic Diseases
- Autoimmune Diseases
- Infections
- Others
- Diagnostics
- Microbiome Profiling
- Disease Diagnosis
- Treatment Decision Support
- Food & Beverages
- Personal Care
- Veterinary
By Disease Type
- Obesity
- Diabetes
- Autoimmune Disorder
- Metabolic and Gastrointestinal Disorders
- Cancer
- Others
By Technology
- Sequencing Technologies
- Microarray Technologies
- PCR (Polymerase Chain Reaction)
- Metabolomics
- Others
Market Segments Covered in the Report (Additional can be Customized)
Table of Content
Table of Contents
Chapter 1. Overview
1.1 Report Description and Scope
1.2 Research scope
1.3 Research methodology
1.3.1 Market Research Type
1.3.2 Market Research Methodology
Chapter 2. Executive Summary
2.1 Global Human Microbiome Market, (2024 – 2033) (USD Million)
2.2 Global Human Microbiome Market: snapshot
Chapter 3. Global Human Microbiome Market – Industry Analysis
3.1 Human Microbiome Market: Market Dynamics
3.2 Market Drivers
3.2.1 Advancements in Technology
3.2.2 Growing Awareness of Microbiome’s Role in Health
3.2.3 Rising Prevalence of Chronic Diseases
3.2.4 Expanding Applications Across Industries
3.2.5 Personalized Medicine
3.2.6 Development of Next-Generation Therapeutics.
3.3 Market Restraints
3.4 Market Opportunities
3.5 Market Challenges
3.6 Porter’s Five Forces Analysis
3.7 Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis By Product Type
3.7.2 Market Attractiveness Analysis By Application
3.7.3 Market Attractiveness Analysis By Technology
3.7.4 Market Attractiveness Analysis By Disease Type
Chapter 4. Global Human Microbiome Market- Competitive Landscape
4.1 Company market share analysis
4.1.1 Global Human Microbiome Market: Company Market Share, 2023
4.2 Strategic development
4.2.1 Acquisitions & mergers
4.2.2 New Product launches
4.2.3 Agreements, partnerships, cullaborations, and joint ventures
4.2.4 Research and development and Regional expansion
4.3 Price trend analysis
Chapter 5. Global Human Microbiome Market – Product Type Analysis
5.1 Global Human Microbiome Market Overview: By Product Type
5.1.1 Global Human Microbiome Market Share, By Product Type, 2023 and 2033
5.2 Probiotics
5.2.1 Global Human Microbiome Market by Probiotics, 2024 – 2033 (USD Million)
5.3 Prebiotics
5.3.1 Global Human Microbiome Market by Prebiotics, 2024 – 2033 (USD Million)
5.4 Medical Foods
5.4.1 Global Human Microbiome Market by Medical Foods, 2024 – 2033 (USD Million)
5.5 Drugs
5.5.1 Global Human Microbiome Market by Drugs, 2024 – 2033 (USD Million)
5.6 Diagnostic Tests
5.6.1 Global Human Microbiome Market by Diagnostic Tests, 2024 – 2033 (USD Million)
Chapter 6. Global Human Microbiome Market – Application Analysis
6.1 Global Human Microbiome Market Overview: By Application
6.1.1 Global Human Microbiome Market Share, By Application, 2023 and 2033
6.2 Therapeutics
6.2.1 Global Human Microbiome Market by Therapeutics, 2024 – 2033 (USD Million)
6.3 Gastrointestinal Disorders
6.3.1 Global Human Microbiome Market by Gastrointestinal Disorders, 2024 – 2033 (USD Million)
6.4 Metabolic Diseases
6.4.1 Global Human Microbiome Market by Metabolic Diseases, 2024 – 2033 (USD Million)
6.5 Autoimmune Diseases
6.5.1 Global Human Microbiome Market by Autoimmune Diseases, 2024 – 2033 (USD Million)
6.6 Infections
6.6.1 Global Human Microbiome Market by Infections, 2024 – 2033 (USD Million)
6.7 Others
6.7.1 Global Human Microbiome Market by Others, 2024 – 2033 (USD Million)
6.8 Diagnostics
6.8.1 Global Human Microbiome Market by Diagnostics, 2024 – 2033 (USD Million)
6.9 Microbiome Profiling
6.9.1 Global Human Microbiome Market by Microbiome Profiling, 2024 – 2033 (USD Million)
6.10 Disease Diagnosis
6.10.1 Global Human Microbiome Market by Disease Diagnosis, 2024 – 2033 (USD Million)
6.11 Treatment Decision Support
6.11.1 Global Human Microbiome Market by Treatment Decision Support, 2024 – 2033 (USD Million)
6.12 Food & Beverages
6.12.1 Global Human Microbiome Market by Food & Beverages, 2024 – 2033 (USD Million)
6.13 Personal Care
6.13.1 Global Human Microbiome Market by Personal Care, 2024 – 2033 (USD Million)
6.14 Veterinary
6.14.1 Global Human Microbiome Market by Veterinary, 2024 – 2033 (USD Million)
Chapter 7. Global Human Microbiome Market – Technology Analysis
7.1 Global Human Microbiome Market overview: By Technology
7.1.1 Global Human Microbiome Market share, By Technology, 2023 and 2033
7.2 Sequencing Technologies
7.2.1 Global Human Microbiome Market by Sequencing Technologies, 2024 – 2033 (USD Million)
7.3 Microarray Technologies
7.3.1 Global Human Microbiome Market by Microarray Technologies, 2024 – 2033 (USD Million)
7.4 PCR (Polymerase Chain Reaction)
7.4.1 Global Human Microbiome Market by PCR (Polymerase Chain Reaction), 2024 – 2033 (USD Million)
7.5 Metabolomics
7.5.1 Global Human Microbiome Market by Metabolomics, 2024 – 2033 (USD Million)
7.6 Others
7.6.1 Global Human Microbiome Market by Others, 2024 – 2033 (USD Million)
Chapter 8. Global Human Microbiome Market – Disease Type Analysis
8.1 Global Human Microbiome Market Overview: By Disease Type
8.1.1 Global Human Microbiome Market Share, By Disease Type, 2023 and 2033
8.2 Obesity
8.2.1 Global Human Microbiome Market by Obesity, 2024 – 2033 (USD Million)
8.3 Diabetes
8.3.1 Global Human Microbiome Market by Diabetes, 2024 – 2033 (USD Million)
8.4 Autoimmune Disorder
8.4.1 Global Human Microbiome Market by Autoimmune Disorder, 2024 – 2033 (USD Million)
8.5 Metabolic and Gastrointestinal Disorders
8.5.1 Global Human Microbiome Market by Metabolic and Gastrointestinal Disorders, 2024 – 2033 (USD Million)
8.6 Cancer
8.6.1 Global Human Microbiome Market by Cancer, 2024 – 2033 (USD Million)
8.7 Others
8.7.1 Global Human Microbiome Market by Others, 2024 – 2033 (USD Million)
Chapter 9. Human Microbiome Market – Regional Analysis
9.1 Global Human Microbiome Market Regional Overview
9.2 Global Human Microbiome Market Share, by Region, 2023 & 2033 (USD Million)
9.3. North America
9.3.1 North America Human Microbiome Market, 2024 – 2033 (USD Million)
9.3.1.1 North America Human Microbiome Market, by Country, 2024 – 2033 (USD Million)
9.4 North America Human Microbiome Market, by Product Type, 2024 – 2033
9.4.1 North America Human Microbiome Market, by Product Type, 2024 – 2033 (USD Million)
9.5 North America Human Microbiome Market, by Application, 2024 – 2033
9.5.1 North America Human Microbiome Market, by Application, 2024 – 2033 (USD Million)
9.6 North America Human Microbiome Market, by Technology, 2024 – 2033
9.6.1 North America Human Microbiome Market, by Technology, 2024 – 2033 (USD Million)
9.7 North America Human Microbiome Market, by Disease Type, 2024 – 2033
9.7.1 North America Human Microbiome Market, by Disease Type, 2024 – 2033 (USD Million)
9.8. Europe
9.8.1 Europe Human Microbiome Market, 2024 – 2033 (USD Million)
9.8.1.1 Europe Human Microbiome Market, by Country, 2024 – 2033 (USD Million)
9.9 Europe Human Microbiome Market, by Product Type, 2024 – 2033
9.9.1 Europe Human Microbiome Market, by Product Type, 2024 – 2033 (USD Million)
9.10 Europe Human Microbiome Market, by Application, 2024 – 2033
9.10.1 Europe Human Microbiome Market, by Application, 2024 – 2033 (USD Million)
9.11 Europe Human Microbiome Market, by Technology, 2024 – 2033
9.11.1 Europe Human Microbiome Market, by Technology, 2024 – 2033 (USD Million)
9.12 Europe Human Microbiome Market, by Disease Type, 2024 – 2033
9.12.1 Europe Human Microbiome Market, by Disease Type, 2024 – 2033 (USD Million)
9.13. Asia Pacific
9.13.1 Asia Pacific Human Microbiome Market, 2024 – 2033 (USD Million)
9.13.1.1 Asia Pacific Human Microbiome Market, by Country, 2024 – 2033 (USD Million)
9.14 Asia Pacific Human Microbiome Market, by Product Type, 2024 – 2033
9.14.1 Asia Pacific Human Microbiome Market, by Product Type, 2024 – 2033 (USD Million)
9.15 Asia Pacific Human Microbiome Market, by Application, 2024 – 2033
9.15.1 Asia Pacific Human Microbiome Market, by Application, 2024 – 2033 (USD Million)
9.16 Asia Pacific Human Microbiome Market, by Technology, 2024 – 2033
9.16.1 Asia Pacific Human Microbiome Market, by Technology, 2024 – 2033 (USD Million)
9.17 Asia Pacific Human Microbiome Market, by Disease Type, 2024 – 2033
9.17.1 Asia Pacific Human Microbiome Market, by Disease Type, 2024 – 2033 (USD Million)
9.18. Latin America
9.18.1 Latin America Human Microbiome Market, 2024 – 2033 (USD Million)
9.18.1.1 Latin America Human Microbiome Market, by Country, 2024 – 2033 (USD Million)
9.19 Latin America Human Microbiome Market, by Product Type, 2024 – 2033
9.19.1 Latin America Human Microbiome Market, by Product Type, 2024 – 2033 (USD Million)
9.20 Latin America Human Microbiome Market, by Application, 2024 – 2033
9.20.1 Latin America Human Microbiome Market, by Application, 2024 – 2033 (USD Million)
9.21 Latin America Human Microbiome Market, by Technology, 2024 – 2033
9.21.1 Latin America Human Microbiome Market, by Technology, 2024 – 2033 (USD Million)
9.22 Latin America Human Microbiome Market, by Disease Type, 2024 – 2033
9.22.1 Latin America Human Microbiome Market, by Disease Type, 2024 – 2033 (USD Million)
9.23. The Middle-East and Africa
9.23.1 The Middle-East and Africa Human Microbiome Market, 2024 – 2033 (USD Million)
9.23.1.1 The Middle-East and Africa Human Microbiome Market, by Country, 2024 – 2033 (USD Million)
9.24 The Middle-East and Africa Human Microbiome Market, by Product Type, 2024 – 2033
9.24.1 The Middle-East and Africa Human Microbiome Market, by Product Type, 2024 – 2033 (USD Million)
9.25 The Middle-East and Africa Human Microbiome Market, by Application, 2024 – 2033
9.25.1 The Middle-East and Africa Human Microbiome Market, by Application, 2024 – 2033 (USD Million)
9.26 The Middle-East and Africa Human Microbiome Market, by Technology, 2024 – 2033
9.26.1 The Middle-East and Africa Human Microbiome Market, by Technology, 2024 – 2033 (USD Million)
9.27 The Middle-East and Africa Human Microbiome Market, by Disease Type, 2024 – 2033
9.27.1 The Middle-East and Africa Human Microbiome Market, by Disease Type, 2024 – 2033 (USD Million)
Chapter 10. Company Profiles
10.1 Seres Therapeutics Inc.
10.1.1 Overview
10.1.2 Financials
10.1.3 Product Portfolio
10.1.4 Business Strategy
10.1.5 Recent Developments
10.2 Second Genome Inc.
10.2.1 Overview
10.2.2 Financials
10.2.3 Product Portfolio
10.2.4 Business Strategy
10.2.5 Recent Developments
10.3 Rebiotix Inc.
10.3.1 Overview
10.3.2 Financials
10.3.3 Product Portfolio
10.3.4 Business Strategy
10.3.5 Recent Developments
10.4 Vedanta Biosciences Inc.
10.4.1 Overview
10.4.2 Financials
10.4.3 Product Portfolio
10.4.4 Business Strategy
10.4.5 Recent Developments
10.5 uBiome Inc.
10.5.1 Overview
10.5.2 Financials
10.5.3 Product Portfolio
10.5.4 Business Strategy
10.5.5 Recent Developments
10.6 Finch Therapeutics Group Inc.
10.6.1 Overview
10.6.2 Financials
10.6.3 Product Portfolio
10.6.4 Business Strategy
10.6.5 Recent Developments
10.7 4D Pharma PLC
10.7.1 Overview
10.7.2 Financials
10.7.3 Product Portfolio
10.7.4 Business Strategy
10.7.5 Recent Developments
10.8 Microbiome Therapeutics LLC
10.8.1 Overview
10.8.2 Financials
10.8.3 Product Portfolio
10.8.4 Business Strategy
10.8.5 Recent Developments
10.9 Synlogic Inc.
10.9.1 Overview
10.9.2 Financials
10.9.3 Product Portfolio
10.9.4 Business Strategy
10.9.5 Recent Developments
10.10 E. I. du Pont de Nemours and Company (DuPont)
10.10.1 Overview
10.10.2 Financials
10.10.3 Product Portfolio
10.10.4 Business Strategy
10.10.5 Recent Developments
10.11 Viome Inc.
10.11.1 Overview
10.11.2 Financials
10.11.3 Product Portfolio
10.11.4 Business Strategy
10.11.5 Recent Developments
10.12 CoreBiome Inc.
10.12.1 Overview
10.12.2 Financials
10.12.3 Product Portfolio
10.12.4 Business Strategy
10.12.5 Recent Developments
10.13 Assembly Biosciences Inc.
10.13.1 Overview
10.13.2 Financials
10.13.3 Product Portfolio
10.13.4 Business Strategy
10.13.5 Recent Developments
10.14 Locus Biosciences Inc.
10.14.1 Overview
10.14.2 Financials
10.14.3 Product Portfolio
10.14.4 Business Strategy
10.14.5 Recent Developments
10.15 Seed Health
10.15.1 Overview
10.15.2 Financials
10.15.3 Product Portfolio
10.15.4 Business Strategy
10.15.5 Recent Developments
10.16 Others.
10.16.1 Overview
10.16.2 Financials
10.16.3 Product Portfolio
10.16.4 Business Strategy
10.16.5 Recent Developments
Key Players
Key Players-
- Seres Therapeutics Inc.
- Second Genome Inc.
- Rebiotix Inc.
- Vedanta Biosciences Inc.
- uBiome Inc.
- Finch Therapeutics Group Inc.
- 4D Pharma PLC
- Microbiome Therapeutics LLC
- Synlogic Inc.
- I. du Pont de Nemours and Company (DuPont)
- Viome Inc.
- CoreBiome Inc.
- Assembly Biosciences Inc.
- Locus Biosciences Inc.
- Seed Health
- Others
